Authors: Shivani Harikrishnan, Sangeetha Shyam, Suan Phaik Khoo.

ABSTRACT

Recent studies have theorised that visfatin plays a significant role in the development and progression of Type 2 Diabetes Mellitus (T2DM). Some studies indicate that levels of serum visfatin are increased in subjects with T2DM whereas other studies dispute this claim. Since the results of these studies remain inconsistent, a systematic review and meta-analysis were performed. A search of PubMed, Ebsco-MEDLINE, Scopus, ScienceDirect, and Cochrane was conducted up till February 2019. Data analysis was performed using Review Manager 5.3. The standardised mean difference (SMD) with a 95% confidence interval (CI) was used to pool the effect size. The Newcastle Ottawa scale (NOS) was used to evaluate bias in the selected studies and a funnel plot was used to assess publication bias. A total of 17 studies were included in this systematic review and meta-analysis. Overall, levels of serum visfatin in subjects with T2DM were significantly higher when compared to the healthy adults (SMD: 1.68 95% CI [1.22,2.14], p<0.00001, I2=92%). Sensitivity and subgroup analyses did not decrease heterogeneity. Among subjects with T2DM, those with additional comorbidity showed moderately increased levels of serum visfatin when compared to the subjects without comorbidity (SMD: 0.73 95% CI [0.14,1.32], p< 0.00001, I2=92%). Sensitivity and subgroup analyses performed did not significantly decrease heterogeneity. Levels of serum visfatin are increased in subjects with T2DM when compared to healthy adults. Levels of serum visfatin are increased in subjects with T2DM with comorbidity when compared to subjects with T2DM without comorbidity. However, these findings must be interpreted with caution as high heterogeneity (I2=92%) was observed.

Keywords: Serum visfatin, Type 2 Diabetes Mellitus, Systematic Review, Meta-Analysis.

Citation: IeJSME 2021 15 (3): 5-20

DOI: https://doi.org/10.56026/imu.15.3.5